GlassScriptPhysician profile
Rajat Bhalla
NPI 1063857001
$2,989.48
in general payments reported to CMS, 2019-2025
31 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $1,057 · 2022: $119 · 2024: $192 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682 · Education: $7.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.32 |
| Education | $7.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $454.06 | 2021-2025 | Tepezza, Evenity |
| Novo Nordisk INC | $431.90 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.31 | 2021-2022 | |
| Mannkind Corporation | $205.23 | 2021-2025 | |
| Medtronic, INC. | $190.91 | 2021-2025 | Minimed 780g |
| Lilly USA, LLC | $188.52 | 2021-2025 | Mounjaro, Zepbound |
| Ascendis Pharma Endocrinology INC | $173.77 | 2025 | Yorvipath |
| Xeris Pharmaceuticals, INC. | $144.53 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $143.50 | 2021 | |
| Abbott Laboratories | $81.71 | 2024-2025 | Freestyle Libre 3 |
| Pfizer INC. | $78.00 | 2019 | |
| Corcept Therapeutics | $68.95 | 2025 | Korlym |
| Grt US Holding, INC. | $65.61 | 2021 | |
| Sanofi-Aventis U.S. LLC | $57.39 | 2021-2025 | |
| Madrigal Pharmaceuticals | $46.70 | 2025 | Rezdiffra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $44.55 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $29.36 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $24.26 | 2021 | |
| Boston Scientific Corporation | $22.08 | 2024 | |
| Abbvie INC. | $20.02 | 2021 | |
| Tandem Diabetes Care, INC. | $19.64 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $19.56 | 2021 | |
| Ibsa Pharma INC. | $19.07 | 2025 | Flector, Tirosint, Licart |
| Alfasigma USA, INC. | $18.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.91 | 2019 | |
| Astellas Pharma US INC | $17.80 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $16.91 | 2019 | |
| Averitas Pharma INC. | $15.67 | 2024 | Qutenza |
| Antares Pharma, INC. | $13.78 | 2021 | |
| Zealand Pharma US, INC. | $13.35 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajat Bhalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.